Sector Gamma AS acquired a new position in Agios Pharmaceuticals (NASDAQ:AGIO) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 41,000 shares of the biopharmaceutical company’s stock, valued at approximately $3,353,000. Agios Pharmaceuticals makes up about 0.6% of Sector Gamma AS’s holdings, making the stock its 28th largest holding. Sector Gamma AS owned about 0.07% of Agios Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also modified their holdings of the stock. Neuberger Berman Group LLC raised its stake in Agios Pharmaceuticals by 1,349.4% in the first quarter. Neuberger Berman Group LLC now owns 234,940 shares of the biopharmaceutical company’s stock worth $19,213,000 after buying an additional 218,730 shares in the last quarter. Aperio Group LLC acquired a new position in shares of Agios Pharmaceuticals during the first quarter worth $311,000. Schwab Charles Investment Management Inc. increased its position in shares of Agios Pharmaceuticals by 24.5% during the first quarter. Schwab Charles Investment Management Inc. now owns 151,812 shares of the biopharmaceutical company’s stock worth $12,416,000 after purchasing an additional 29,837 shares in the last quarter. Hood River Capital Management LLC increased its position in shares of Agios Pharmaceuticals by 2.1% during the first quarter. Hood River Capital Management LLC now owns 133,322 shares of the biopharmaceutical company’s stock worth $10,903,000 after purchasing an additional 2,705 shares in the last quarter. Finally, State of Wisconsin Investment Board increased its position in shares of Agios Pharmaceuticals by 15.7% during the first quarter. State of Wisconsin Investment Board now owns 9,904 shares of the biopharmaceutical company’s stock worth $810,000 after purchasing an additional 1,345 shares in the last quarter. 82.13% of the stock is owned by institutional investors.
A number of equities analysts have recently issued reports on AGIO shares. Royal Bank of Canada upped their price target on Agios Pharmaceuticals to $91.00 and gave the stock an “outperform” rating in a research report on Thursday, January 18th. They noted that the move was a valuation call. JPMorgan Chase upped their price target on Agios Pharmaceuticals from $76.00 to $85.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. BidaskClub raised Agios Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 3rd. ValuEngine raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, SunTrust Banks set a $115.00 price target on Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, May 7th. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $88.40.
Shares of AGIO opened at $86.20 on Thursday. The firm has a market cap of $4.92 billion, a PE ratio of -12.77 and a beta of 1.98. Agios Pharmaceuticals has a 1-year low of $85.15 and a 1-year high of $86.25.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Friday, May 4th. The biopharmaceutical company reported ($1.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.03). The company had revenue of $8.80 million for the quarter, compared to analysts’ expectations of $11.93 million. Agios Pharmaceuticals had a negative net margin of 822.32% and a negative return on equity of 61.70%. Agios Pharmaceuticals’s quarterly revenue was down 16.2% compared to the same quarter last year. During the same period last year, the firm earned ($1.56) earnings per share. analysts predict that Agios Pharmaceuticals will post -6.51 EPS for the current fiscal year.
In other news, CEO David P. Schenkein sold 13,000 shares of the business’s stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $81.09, for a total transaction of $1,054,170.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Christopher Bowden sold 2,000 shares of the business’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $77.65, for a total transaction of $155,300.00. The disclosure for this sale can be found here. Insiders have sold 64,950 shares of company stock worth $5,258,138 over the last three months. Corporate insiders own 3.02% of the company’s stock.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.